Tag: Divarasib

Roche’s divarasib improved median overall survival to 17.7 months versus 12.0 months with sotorasib or adagrasib in Phase 3 Krascendo 1. The findings inform treatment choice in KRAS G12C-mutated lung cancer but do not establish efficacy after KRAS-inhibitor resistance.